Evofem Narrows Q3 Loss Amidst Sales Dip, Royalty Gain Boosts Bottom Line

Ticker: EVFM · Form: 10-Q · Filed: Nov 13, 2025 · CIK: 1618835

Sentiment: bearish

Topics: Biotechnology, Pharmaceuticals, Financial Performance, Net Loss, Product Sales, Going Concern, Risk Factors

Related Tickers: EVFM

TL;DR

**Evofem is still bleeding cash and relying on accounting gains; this stock is a speculative gamble at best.**

AI Summary

Evofem Biosciences, Inc. reported a net loss of $1.569 million for the three months ended September 30, 2025, an improvement from a net loss of $2.365 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $2.397 million, significantly better than the $5.823 million loss in the prior year. Product sales, net, increased to $4.952 million in Q3 2025 from $4.496 million in Q3 2024, but decreased for the nine-month period to $10.622 million from $12.259 million. The company recorded a significant gain of $1.933 million on change in accounting estimates on contingent royalty liability in Q3 2025. Total current assets decreased from $13.609 million at December 31, 2024, to $7.918 million at September 30, 2025, while total current liabilities slightly decreased from $80.448 million to $78.186 million. The company's accumulated deficit grew to $900.176 million by September 30, 2025, from $897.664 million at December 31, 2024, and it continues to operate with a total stockholders' deficit of $75.066 million.

Why It Matters

Evofem's ability to narrow its net loss, despite a nine-month sales decline, is a critical signal for investors, suggesting potential operational efficiencies or one-time gains. The significant gain from a change in contingent royalty liability accounting estimates, at $1.933 million, indicates a non-recurring positive impact that investors should scrutinize for sustainability. For employees and customers, the company's ongoing financial instability, evidenced by a substantial accumulated deficit and negative stockholders' equity, raises questions about long-term viability and product support. In a competitive pharmaceutical market, Evofem's struggle to achieve consistent profitability and positive cash flow could make it vulnerable to larger, better-capitalized rivals, impacting its ability to innovate and expand market share for products like PHEXX and SOLOSEC.

Risk Assessment

Risk Level: high — Evofem Biosciences, Inc. exhibits a high risk level due to its substantial accumulated deficit of $900.176 million and a total stockholders' deficit of $75.066 million as of September 30, 2025. The company also reported negative cash flows from operating activities, with a net cash used of $2.397 million for the nine months ended September 30, 2025, indicating ongoing operational losses and a reliance on external financing to sustain operations.

Analyst Insight

Investors should exercise extreme caution and consider divesting any holdings in EVFM. The company's persistent accumulated deficit and negative stockholders' equity, coupled with declining nine-month product sales, suggest a challenging path to sustainable profitability. Focus on companies with strong balance sheets and consistent positive cash flow.

Financial Highlights

debt To Equity
N/A
revenue
$4.952M
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$1.569M
eps
N/A
gross Margin
N/A
cash Position
$7.918M
revenue Growth
+10.15%

Revenue Breakdown

SegmentRevenueGrowth
Product Sales, Net$4.952M+10.15%

Key Numbers

Key Players & Entities

FAQ

What were Evofem Biosciences' net product sales for the third quarter of 2025?

Evofem Biosciences, Inc. reported net product sales of $4.952 million for the three months ended September 30, 2025. This represents an increase from $4.496 million in the same period of 2024.

How did Evofem Biosciences' net loss change in Q3 2025 compared to Q3 2024?

Evofem Biosciences' net loss for the three months ended September 30, 2025, was $1.569 million, which is an improvement from the net loss of $2.365 million reported in the third quarter of 2024.

What is Evofem Biosciences' accumulated deficit as of September 30, 2025?

As of September 30, 2025, Evofem Biosciences, Inc. had an accumulated deficit of $900.176 million. This figure increased from $897.664 million at December 31, 2024.

What was the impact of the gain on change in accounting estimates on contingent royalty liability for Evofem Biosciences?

Evofem Biosciences recorded a significant gain of $1.933 million on change in accounting estimates on contingent royalty liability for both the three and nine months ended September 30, 2025. This gain positively impacted the company's operating expenses and overall net loss.

What are the primary risks to Evofem Biosciences' ability to continue as a going concern?

Evofem Biosciences faces significant risks to its going concern ability, including its substantial accumulated deficit of $900.176 million, negative cash flows from operations, and the need to raise additional capital. The company also highlights risks related to potential legal actions from a Notice of Default and cancellation of Forbearance Agreement with Future Pak, LLC.

How many shares of Evofem Biosciences' Common Stock were outstanding as of November 12, 2025?

As of November 12, 2025, the number of shares of Evofem Biosciences' Common Stock, $0.0001 par value per share, outstanding was 126,685,925.

What products does Evofem Biosciences commercialize?

Evofem Biosciences commercializes SOLOSEC (secnidazole) 2g oral granules and PHEXX (lactic acid, citric acid, and potassium bitartrate) vaginal gel, which was formerly known as PHEXXI.

Did Evofem Biosciences experience a change in fair value of financial instruments in Q3 2025?

Yes, Evofem Biosciences reported a change in fair value of financial instruments resulting in a loss of $1.845 million for the three months ended September 30, 2025, compared to a gain of $769 thousand in the same period of 2024.

What was the trend in Evofem Biosciences' total current assets and liabilities?

Evofem Biosciences' total current assets decreased from $13.609 million at December 31, 2024, to $7.918 million at September 30, 2025. Total current liabilities slightly decreased from $80.448 million to $78.186 million over the same period.

What is the significance of the 'One Big Beautiful Bill Act' for Evofem Biosciences?

Evofem Biosciences states that the passage of the 'One Big Beautiful Bill Act' has the potential for substantial negative impact on contraception access and STI treatment, especially for low-income and uninsured women, which could affect the market for their products.

Risk Factors

Industry Context

Evofem operates in the highly competitive women's health and contraceptive market. The market is characterized by established pharmaceutical companies and a growing demand for innovative and convenient solutions. Key trends include a focus on non-hormonal options and direct-to-consumer marketing strategies.

Regulatory Implications

As a pharmaceutical company, Evofem is subject to stringent regulatory oversight by bodies like the FDA. Compliance with manufacturing standards, marketing regulations, and post-market surveillance is critical. Any failure to comply can result in significant penalties, product recalls, and reputational damage.

What Investors Should Do

  1. Monitor Phexxi sales trajectory closely.
  2. Assess the sustainability of the Q3 2025 net loss improvement.
  3. Evaluate the company's ability to secure additional funding.
  4. Scrutinize the 'Gain on Contingent Royalty Liability'.

Key Dates

Glossary

Accumulated Deficit
The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's long-term profitability and financial health. Evofem's growing accumulated deficit to $900.176 million is a significant concern.)
Stockholders' Deficit
Occurs when a company's liabilities exceed its assets, resulting in a negative net worth for shareholders. (Evofem's total stockholders' deficit of $75.066 million highlights its negative equity position.)
Contingent Royalty Liability
A liability that may arise in the future depending on the occurrence of a specific event or condition, often related to intellectual property or licensing agreements. (A gain on change in accounting estimates for this liability ($1.933 million) significantly impacted Q3 2025 net income, masking underlying operational performance.)
Going Concern
The assumption that a company will continue to operate for the foreseeable future, typically at least 12 months. (The company's financial condition raises substantial doubt about its ability to continue as a going concern, a critical factor for investors and creditors.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Evofem Biosciences experienced a significant reduction in net loss, from $5.823 million to $2.397 million, indicating improved cost management or operational efficiency. However, product sales for the nine-month period declined from $12.259 million to $10.622 million, suggesting challenges in sales volume or pricing. While current assets have decreased substantially, current liabilities have seen a slight reduction, but the overall working capital position remains a concern.

Filing Stats: 4,726 words · 19 min read · ~16 pages · Grade level 20 · Accepted 2025-11-13 16:01:20

Filing Documents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 1 PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Operations 5 Condensed Consolidated Statements of Convertible and Redeemable Preferred Stock and Stockholders' Deficit 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 34 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 43 Item 4.

Controls and Procedures

Controls and Procedures 43 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 45 Item 1A.

Risk Factors

Risk Factors 45 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 45 Item 3. Defaults Upon Senior Securities 45 Item 4. Mine Safety Disclosures 45 Item 5. Other Information 45 Item 6. Exhibits 45

Signatures

Signatures 46 FORWARD-LOOKING This quarterly report on Form 10-Q (Quarterly Report), contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations." All statements, other than statements of historical facts, contained in this Quarterly Report, including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. Words such as, but not limited to, "anticipate," "aim," "believe," "contemplate," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These

forward-looking statements include, among other things, statements about

forward-looking statements include, among other things, statements about: our ability to continue as a going concern; risks and uncertainties related to changes in government operations, including a federal government shutdown, which could delay our ability to offer registered securities, FDA reviews, disrupt supply chains, or affect healthcare reimbursement decisions; the Notice of Default and cancellation of Forbearance Agreement received by Future Pak, LLC and any potential legal action(s) against the Company, including that its assets that could be taken and potential negative outcome(s) thereof; our ability to successfully commercialize SOLOSEC (secnidazole) 2g oral granules (SOLOSEC); our ability to remediate the material weaknesses in our internal controls and procedures identified by management; our ability to obtain necessary approvals of any corporate action(s) needing stockholder, FINRA, Nasdaq, or other approvals; our ability to file Annual and Quarterly Reports on a timely basis; our ability to raise additional capital to fund our operations if and as needed; our ability to achieve and sustain profitability; our estimates regarding our future performance including, without limitation, any estimates of potential future revenues; estimates regarding market size; our estimates regarding expenses, revenues, financial performance, and capital requirements, including the length of time our capital resources will sustain our operations; our ability to comply with the provisions and requirements of our debt arrangements, to avoid future defaults pursuant to our debt arrangements, and to pay amounts owed, including any amounts that may be accelerated, pursuant to our debt arrangements; estimates regarding health care providers' (HCPs') recommendations of PHEXX (formerly known as PHEXXI) (lactic acid, citric acid, and potassium bitartrate) vaginal gel (PHEXX) to patients; estimates regarding HCPs' recommendations of SOLOSEC to patient

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing